Phase III TAK-620-303 (SOLSTICE) trial of TAK 620 meets primary endpoint in cytomegalovirus infection.- Takeda
Takeda announced new, late-breaking Phase III data from the TAK-620-303 (SOLSTICE) trial, for the investigational drug TAK 620 (maribavir) which met its primary endpoint of superiority compared to conventional antiviral therapies (investigator assigned treatment, [IAT], one or a combination of ganciclovir, valganciclovir, foscarnet or cidofovir) in transplant recipients with refractory, with or without resistance (R/R), cytomegalovirus (CMV) infection/disease.